BioSpace News Archive

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Zimmer Biomet Holdings, Inc., a global medical technology leader, published its 2023 Sustainability Report which provides an overview of the company’s environmental, social and governance program, progress, and accomplishments.

Relmada Therapeutics, Inc. announced that it will report its financial results for the first quarter ended March 31, 2024 after the market close on Wednesday, May 8, 2024.

EDAP TMS SA announced a recent presentation highlighting the positive, final results from a large, prospective, multicenter, non-inferiority study, the HIFI Study, comparing Focal One® high intensity focused ultrasound versus radical prostatectomy at the 119th American Urological Association Annual Meeting, which took place from May 3-6, 2024, in San Antonio, Texas, USA.

PROCEPT BioRobotics® Corporation, a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced long-term, real-world data showcasing the benefits of Aquablation therapy for the treatment of symptomatic benign prostatic hyperplasia at both academic and commercial settings.

Akoya Biosciences, Inc., The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms.

aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2024.

Sagimet Biosciences Inc. announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.

Fate Therapeutics, Inc. will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results.

Krystal Biotech, Inc. today reported financial results and key business updates for the first quarter ending March 31, 2024.